Clinigen has made a series of organisational changes that it says will help it achieve its five-year growth targets.
The company has appointed Shaun Chilton chief operating officer for the group in a move that will also see him take on management of its Specialty Pharmaceuticals (SP) business to his responsibilities.
Chilton (pictured), who was previously chief operating officer for Clinigen’s CTS (Clinical Trial Supply) and GAP (Global Access Programs) business, has been with the company since January 2012.
Prior to joining the UK-headquartered speciality pharmaceutical products firm, Chilton held a series of senior roles at companies that included KnowledgePoint360, Acumed and Adis International.
As part of its management reshuffle Clinigen has also appointed a trio of new senior vice presidents to run its three operating businesses.
Mark Corbett will lead Clinigen GAP, Lorann Morse will become senior vice president for Clinigen CTS and David Bryant will head up Clinigen SP.
The changes will also see Anton Jenkins, who was previously chief operating office for Clinigen SP move to the role of business development director to focus on in-licensing and acquiring new products.
Peter George, Clinigen Group’s CEO, said: “Over the past three years, we have seen significant organic growth of CTS and GAP and the expansion of our product portfolio with the acquisition of Cardioxane from Novartis and in-licensing of Vibativ from Theravance.
“Now is a logical time for us to ensure we have the right infrastructure and people in place to be able to scale-up further for future growth and achieve our ambitious plans.”